[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

Upstate Institutional Review Board (IRB) Number:

1445012

Study/Protocol ID:

XL184-313

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

What is involved if I participate?

  • How long is the study?
    2 years, then maintenance
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No

Where will the study take place?

Upstate Cancer Center
Main University Hospital

ClinicalTrials.Gov ID:

NCT03937219

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Alexandra Koulouris, BA
Phone: 315-464-8237
Email: kouloura@upstate.edu

Return to Previous Page || Search Again

Top